These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16585161)

  • 1. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S; Shannon K; Bollag G
    Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
    Emuss V; Garnett M; Mason C; Marais R
    Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
    Ikenoue T; Kanai F; Hikiba Y; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Asaoka Y; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Mol Carcinog; 2005 May; 43(1):59-63. PubMed ID: 15791648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
    Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
    Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
    Arthan D; Hong SK; Park JI
    Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
    Gallagher AP; Burnett AK; Bowen DT; Darley RL
    Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.